Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
22
01
2024
accepted:
25
03
2024
revised:
21
03
2024
medline:
6
4
2024
pubmed:
6
4
2024
entrez:
5
4
2024
Statut:
epublish
Résumé
Although increased aerobic glycolysis is common in various cancers, pancreatic ductal adenocarcinoma (PDAC) cells can survive a state of glycolysis suppression. We aimed to identify potential therapeutic targets in glycolysis-suppressed PDAC cells. By screening anticancer metabolic compounds, we identified SP-2509, an inhibitor of lysine-specific histone demethylase 1A (LSD1), which dramatically decreased the growth of PDAC PANC-1 cells and showed an anti-tumoral effect in tumor-bearing mice. The growth of glycolysis-suppressed PANC-1 cells was also inhibited by another LSD1 inhibitor, OG-L002. Similarly, the other two PDAC cells (PK-1 and KLM-1) with suppressed glycolysis exhibited anticancer effects against SP-2509. However, the anticancer effects on PDAC cells were unrelated to LSD1. To investigate how PDAC cells survive in a glycolysis-suppressed condition, we conducted proteomic analyses. These results combined with our previous findings suggested that glucose-starvation causes PDAC cells to enhance mitochondrial oxidative phosphorylation. In particular, mitochondrial fatty acid metabolism was identified as a key factor contributing to the survival of PDAC cells under glycolysis suppression. We further demonstrated that SP-2509 and OG-L002 disturbed fatty acid metabolism and induced lipid droplet accumulation through the impairment of lipophagy, but not bulk autophagy. These findings indicate a significant potential association of lipophagy and anticancer effects in glycolysis-suppressed PDAC cells, offering ideas for new therapeutic strategies for PDAC by dual inhibition of glycolysis and fatty acids metabolism.
Identifiants
pubmed: 38580661
doi: 10.1038/s41420-024-01933-4
pii: 10.1038/s41420-024-01933-4
doi:
Types de publication
Journal Article
Langues
eng
Pagination
166Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 22K19368
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19K16440
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19KK0399
Informations de copyright
© 2024. The Author(s).
Références
Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30.
pubmed: 16982728
doi: 10.1158/0008-5472.CAN-06-1501
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–9.
pubmed: 15172999
doi: 10.1158/0008-5472.CAN-03-2904
Hu CJ, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23:9361–74.
pubmed: 14645546
pmcid: 309606
doi: 10.1128/MCB.23.24.9361-9374.2003
Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ. 2008;15:621–7.
pubmed: 18259201
doi: 10.1038/cdd.2008.12
Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int. 2016;16:9.
pubmed: 26884725
pmcid: 4755025
doi: 10.1186/s12935-016-0280-y
Palorini R, Votta G, Pirola Y, De Vitto H, De Palma S, Airoldi C, et al. Protein kinase A activation promotes cancer cell resistance to glucose starvation and anoikis. PLoS Genet. 2016;12:e1005931.
pubmed: 26978032
pmcid: 4792400
doi: 10.1371/journal.pgen.1005931
Xie J, Wu H, Dai C, Pan Q, Ding Z, Hu D, et al. Beyond Warburg effect–dual metabolic nature of cancer cells. Sci Rep. 2014;4:4927.
pubmed: 24820099
pmcid: 4018627
doi: 10.1038/srep04927
Zaugg K, Yao Y, Reilly PT, Kanna K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011;25:1041–51.
pubmed: 21576264
pmcid: 3093120
doi: 10.1101/gad.1987211
Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020). 2021;2:27–59.
pubmed: 34766135
doi: 10.1002/mco2.27
Perera RM, Bardeesy N. Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov. 2015;5:1247–61.
pubmed: 26534901
pmcid: 4687899
doi: 10.1158/2159-8290.CD-15-0671
Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011;59:942–52.
pubmed: 21832145
pmcid: 3201126
doi: 10.1369/0022155411420569
He Q, Liu Z, Wang J. Targeting KRAS in PDAC: A new way to cure it? Cancers. 2022;14:4982.
pubmed: 36291766
pmcid: 9599866
doi: 10.3390/cancers14204982
Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19:50.
pubmed: 32122374
pmcid: 7053123
doi: 10.1186/s12943-020-01169-7
Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, et al. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep. 2019;9:18699.
pubmed: 31822748
pmcid: 6904735
doi: 10.1038/s41598-019-55296-3
Pelicano H, Martin DS, Xu R-H, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–46.
pubmed: 16892078
doi: 10.1038/sj.onc.1209597
Wu K, Woo SM, Kwon TK. The histone lysine-specific demethylase 1 inhibitor, SP2509 exerts cytotoxic effects against renal cancer cells through downregulation of Bcl-2 and Mcl-1. J Cancer Prev. 2020;25:79–86.
pubmed: 32647649
pmcid: 7337004
doi: 10.15430/JCP.2020.25.2.79
Ahmad M, Wolberg A, Kahwaji CI. Biochemistry, Electron Transport Chain. Treasure Island (FL): StatPearls; 2022.
Zhang S, Yang W, Chen H, Liu B, Lin B, Tao Y. Metabolic engineering for efficient supply of acetyl-CoA from different carbon sources in Escherichia coli. Microb Cell Fact. 2019;18:130.
pubmed: 31387584
pmcid: 6685171
doi: 10.1186/s12934-019-1177-y
Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2017;31:1658.
pubmed: 28322226
doi: 10.1038/leu.2017.77
Zimmer AD, Walbrecq G, Kozar I, Behrmann I, Haan C. Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells. Hypoxia. 2016;4:135–45.
pubmed: 27800515
pmcid: 5085306
doi: 10.2147/HP.S99044
Corbet C, Pinto A, Martherus R, De Jesus JPS, Polet F, Feron O. Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation. Cell Metab. 2016;24:311–23.
pubmed: 27508876
doi: 10.1016/j.cmet.2016.07.003
Wang Y, Lu J-H, Wang F, Wang Y-N, He M-M, Wu Q-N, et al. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. Cancer Lett. 2020;473:74–89.
pubmed: 31904482
doi: 10.1016/j.canlet.2019.12.036
Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14:1435–1455.
pubmed: 29940786
pmcid: 6103682
doi: 10.1080/15548627.2018.1474314
Cruz ALS, Barreto EA, Fazolini NPB, Viola JPB, Bozza PT. Lipid droplets: platforms with multiple functions in cancer hallmarks. Cell Death Dis. 2020;11:105.
pubmed: 32029741
pmcid: 7005265
doi: 10.1038/s41419-020-2297-3
Chao A, Lin C-Y, Chao A-N, Tsai C-L, Chen M-Y, Lee L-Y, et al. Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies. Oncotarget. 2017;8:74434–50.
pubmed: 29088798
pmcid: 5650353
doi: 10.18632/oncotarget.20158
Macheleidt IF, Dalvi PS, Lim S-Y, Meemboor S, Meder L, Kasgen O, et al. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations. Mol Oncol. 2018;12:1965–79.
pubmed: 30220105
pmcid: 6210049
doi: 10.1002/1878-0261.12382
Zhang X, Lu F, Wang J, Yin F, Xu Z, Qi D, et al. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell Rep. 2013;5:445–57.
pubmed: 24139802
doi: 10.1016/j.celrep.2013.09.018
Malagraba G, Yarmohammadi M, Javed A, Barcelo C, Rubio-Tomas T. The role of LSD1 and LSD2 in cancers of the gastrointestinal system: An update. Biomolecules. 2022;12:462.
pubmed: 35327654
pmcid: 8946813
doi: 10.3390/biom12030462
Zhu L, Wang J, Kong W, Huang J, Dong B, Huang Y, et al. LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling. Acta Pharm Sin B. 2019;9:324–34.
pubmed: 30972280
doi: 10.1016/j.apsb.2018.10.006
Pishas KI, Lessnick SL. Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation. Oncotarget. 2018;9:36413–29.
pubmed: 30559927
pmcid: 6284858
doi: 10.18632/oncotarget.26326
Sonnemann J, Zimmermann M, Marx C, Ebert F, Becker S, Lauterjung M-L, et al. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells. Br J Haematol. 2018;183:494–7.
pubmed: 29205263
doi: 10.1111/bjh.14983
Cheng Y, Diao D, Zhang H, Guo Q, Wu X, Song Y, et al. High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose. Biomed Rep. 2014;2:188–92.
pubmed: 24649094
doi: 10.3892/br.2013.211
Voss M, Lorenz MI, Luger A-L, Steinbach JP, Rieger J, Ronellenfitsch MW. Rescue of 2-deoxyglucose side effects by ketogenic diet. Int J Mol Sci. 2018;19:2462.
pubmed: 30127309
pmcid: 6121440
doi: 10.3390/ijms19082462
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.
pubmed: 31819192
doi: 10.1038/s41416-019-0650-z
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–49.
pubmed: 27658529
doi: 10.1038/nrc.2016.89
Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 2022;4:100479.
pubmed: 35469167
pmcid: 9034302
doi: 10.1016/j.jhepr.2022.100479
Wang W, Bai L, Li W, Cui J. The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives. Front Oncol. 2020;10:605154.
pubmed: 33364199
pmcid: 7753360
doi: 10.3389/fonc.2020.605154
Wu X, Geng F, Cheng X, Guo Q, Zhong Y, Cloughesy TF. Lipid droplets maintain energy homeostasis and glioblastoma growth via autophagic release of stored fatty acids. iScience. 2020;23:101569.
pubmed: 33083736
pmcid: 7549116
doi: 10.1016/j.isci.2020.101569
Onal G, Kutlu O, Ozer E, Gozuacik D, Karaduman A, Dokmeci ES. Impairment of lipophagy by PNPLA1 mutations causes lipid droplet accumulation in primary fibroblasts of Autosomal Recessive Congenital Ichthyosis patients. J Dermatol Sci. 2019;93:50–57.
pubmed: 30655104
doi: 10.1016/j.jdermsci.2018.11.013
Maan M, Peters JM, Dutta M, Patterson AD. Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun. 2018;504:582–9.
pubmed: 29438712
pmcid: 6086774
doi: 10.1016/j.bbrc.2018.02.097
Zhang S, Peng X, Yang S, Li X, Huang M, Wei S, et al. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders. Cell Death Dis. 2022;13:132.
pubmed: 35136038
pmcid: 8825858
doi: 10.1038/s41419-022-04593-3
Wang L, Yang Q, Peng S, Liu X. The combination of the glycolysis inhibitor 2DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. Onco Targets Ther. 2019;12:5359–73.
pubmed: 31371980
pmcid: 6635829
doi: 10.2147/OTT.S212465
Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc. 2013;8:1149–54.
pubmed: 23702831
doi: 10.1038/nprot.2013.055